2003
DOI: 10.1038/sj.thj.6200304
|View full text |Cite
|
Sign up to set email alerts
|

Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia

Abstract: This retrospective analysis shows that NE is a serious complication occurring mainly in patients treated by Ara-C administered as continuous i.v. infusion.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
19
0
2

Year Published

2005
2005
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 27 publications
(23 citation statements)
references
References 12 publications
2
19
0
2
Order By: Relevance
“…All of our patients received chemotherapy over the 3 weeks preceding demonstration of fungal infection, in particular they all received cytarabine. Cytarabine is known to alter the integrity of the intestinal mucosal barrier; even in the French experience, the majority of patients were exposed to this agent . Only one of our patients complained of diarrhoea and research of G. clavatum on rectal swabs resulted negative in all.…”
Section: Discussionmentioning
confidence: 56%
“…All of our patients received chemotherapy over the 3 weeks preceding demonstration of fungal infection, in particular they all received cytarabine. Cytarabine is known to alter the integrity of the intestinal mucosal barrier; even in the French experience, the majority of patients were exposed to this agent . Only one of our patients complained of diarrhoea and research of G. clavatum on rectal swabs resulted negative in all.…”
Section: Discussionmentioning
confidence: 56%
“…Prior studies have evaluated the rates of febrile neutropenia, bleeding and invasive fungal infections in AML patients, but these were primarily in the clinical trial setting or were single centre studies and did not present differences by age. (Camera et al , 2003; Lowenberg et al , 2011; De Rosa et al , 2013; Ferrara & Schiffer, 2013; Garcia et al , 2013; Buckley et al , 2014) To our knowledge, no population-based studies have considered the effect of complications on early mortality in AML patients. (Juliusson et al , 2012) Because early mortality continues to be a barrier to improving long-term survival and age is a major prognostic factor, (Juliusson et al , 2009) evaluating the factors that impact early mortality on a population-based level will identify targeted areas for improvement.…”
Section: Introductionmentioning
confidence: 99%
“…Literature indicates that complications in patients being treated for leukemia are increasing [1][2][3][4][5][6][7][8]. This is believed to be secondary to advances in early diagnosis, advanced chemotherapeutic agents coupled with better supportive care leading to higher remission rates, and increased survival.…”
Section: Discussionmentioning
confidence: 97%